Antitumour imidazoacridone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells

被引:38
作者
Hyzy, M [1 ]
Bozko, P [1 ]
Konopa, J [1 ]
Skladanowski, A [1 ]
机构
[1] Gdansk Tech Univ, Dept Pharmaceut Technol & Biochem, Mol & Cellular Biol Lab, PL-80952 Gdansk, Poland
关键词
imidazoacridone; C-1311; cell cycle; G2; arrest; cell death; mitotic catastrophe;
D O I
10.1016/j.bcp.2004.11.028
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this study, we investigated the cell death process induced by imidazoacridone C-1311 (Symadex(TM)) in HT-29 human colon carcinoma cells which have been shown to be preferentially sensitive to this compound in experimental tumour models both in vitro and in nude mice. Compound C-1311 at the EC99 dose delayed progression of cells through the S phase which was followed by G2 arrest. At 4896 h after drug exposure, an increasing fraction of cells rounded up and detached from the substratum which suggested the induction of cell death. This was confirmed by the induction of DNA fragmentation as revealed by pulse field electrophoresis and DNA strand breaks by the TUNEL assay. The dying cells had also mitotic features which were evidenced by various biochemical and morphological criteria such as activation of Cdk1 kinase, presence of the mitotic epitope MPM-2 and condensation of chromatin into mitotic chromosomes in drug-treated cells. These results show that C-1311 does not induce rapid apoptosis in HT-29 cells, instead drug exposure leads to prolonged G2 arrest followed by G2 to M transit and cell death during mitosis in the process of mitotic catastrophe. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:801 / 809
页数:9
相关论文
共 33 条
[1]  
Anderson H, 1996, CELL GROWTH DIFFER, V7, P83
[2]  
Andreassen PR, 2001, CANCER RES, V61, P7660
[3]   Imidazoacridinones arrest cell-cycle progression in the G2 phase of L1210 cells [J].
Augustin, E ;
Wheatley, DN ;
Lamb, J ;
Konopa, J .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 38 (01) :39-44
[4]  
Berger B, 1996, CANCER RES, V56, P2094
[5]  
BERTRAND R, 1991, CANCER RES, V51, P6280
[6]   Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer [J].
Burger, AM ;
Double, JA ;
Konopa, J ;
Bibby, MC .
BRITISH JOURNAL OF CANCER, 1996, 74 (09) :1369-1374
[7]   Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311 [J].
Burger, AM ;
Jenkins, TC ;
Double, JA ;
Bibby, MC .
BRITISH JOURNAL OF CANCER, 1999, 81 (02) :367-375
[8]   Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour-bearing mice [J].
Calabrese, CR ;
Bibby, MC ;
Double, JA ;
Loadman, PM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (05) :379-385
[9]   The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe [J].
Castedo, M ;
Perfettini, JL ;
Roumier, T ;
Yakushijin, K ;
Horne, D ;
Medema, R ;
Kroemer, G .
ONCOGENE, 2004, 23 (25) :4353-4361
[10]   14-3-3σ is required to prevent mitotic catastrophe after DNA damage [J].
Chan, TA ;
Hermeking, H ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
NATURE, 1999, 401 (6753) :616-620